Pharmacological approaches to the modulation of plasma cholesterol.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  TIPS - Trends in Pharmacological Sciences

• Publication date

  1988-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0165-6147(88)90104-6PMID 3078091
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of neomycin sulphate alone and in combination with d-thyroxine on serum lipoproteins in hypercholesterolaemic subjects

  2004cited by this paper
• Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.

  2004cited by this paper
• Synthesis, SARs and therapeutic potential of HMG-CoA reductase inhibitors

  1987cited by this paper
• Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

  1987cited by this paper
• Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

  1987cited by this paper
• Chlorpromazine Inhibits Arterial ACAT and Reduces Arterial Cholesterol and Cholesteryl Ester Accumulation in Cholesterol‐Fed Rabbits

  1986cited by this paper
• Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.

  1986cited by this paper
• Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.

  1985cited by this paper
• Fenofibrate Reduces Low Density Lipoprotein Catabolism in Hypertriglyceridemic Subjects

  1985cited by this paper
• Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

  1984cited by this paper
• Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.

  1984cited by this paper
• Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study.

  1984cited by this paper
• Lipid Research Clinics Program.

  1984cited by this paper
• Turnover of Low Density Lipoproteins during Inhibition of Cholesterol Absorption by Neomycin

  1984cited by this paper
• Cholesterol feeding increases low density lipoprotein synthesis.

  1983cited by this paper
• The hepatobiliary axis and lipoprotein metabolism: effects of bile acid sequestrants and ileal bypass surgery.

  1982cited by this paper
• Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.

  1982cited by this paper
• The Anatomic Evolution of Coronary Artery Disease Demonstrated by Coronary Arteriography in 256 Nonoperated Patients

  1981cited by this paper
• Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.

  1981cited by this paper
• Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism.

  1980cited by this paper
• Treatment of hypercholesterolemia with neomycin--a time for reappraisal.

  1979cited by this paper
• Effects of neomycin alone and in combination with cholestyramine on serum cholesterol and fecal steroids in hypercholesterolemic subjects.

  1979cited by this paper
• [Dose-effect of beta-sitosterin in type IIa and IIb hypercholesterolemias (author's transl)].

  1978cited by this paper
• Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance.

  1977cited by this paper
• ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium.

  1976cited by this paper
• Homozygous familial hypercholesterolemia. A possible biochemical explanation of clinical heterogeneity.

  1975cited by this paper

• Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1.

  2010cites this paper
• Synthetic analogs of phytanic acid and their effect on human hepatic cholesterol esterase in vitro

  2006cites this paper
• Risk reduction therapy for syndrome X: comparison of several treatments.

  2005cites this paper
• The P-407–Induced Murine Model of Dose-Controlled Hyperlipidemia and Atherosclerosis: A Review of Findings To Date

  2004cites this paper
• Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors.

  2004cites this paper
• Synthesis and biological evaluation of quinuclidine derivatives incorporating phenothiazine moieties as squalene synthase inhibitors.

  2004cites this paper
• Inhibitory effects of N-(3,5-dimethoxy-4-n-octyloxycinnamoyl)-N'-(3,4-dimethylphenyl)piperazine (YIC-C8-434), an acyl-CoA:cholesterol O-acyltransferase inhibitor, on cholesterol esterification in the intestine and liver.

  2003cites this paper
• Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors.

  2003cites this paper
• Poloxamer 407-induced atherogenesis in the C57BL/6 mouse.

  1998cites this paper
• The poloxamer 407-induced hyperlipidemic atherogenic animal model.

  1997cites this paper
• Inhibitory effect of monatepil maleate on acyl-CoA:cholesterol acyltransferase activity in the liver of cholesterol-fed Japanese monkeys.

  1997cites this paper
• Antibiotics inhibiting the biosynthesis of cholesterol (a review)

  1997cites this paper
• The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors.

  1996cites this paper
• Effects of Nicotinic Acid on Poloxamer 407‐Induced Hyperlipidemia

  1996cites this paper
• Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats.

  1996cites this paper
• Use of HPLC for the determination of serum 7 alpha-hydroxycholesterol in cholestyramine-treated rats.

  1995cites this paper
• TMP-153, a novel ACAT inhibitor, inhibits cholesterol absorption and lowers plasma cholesterol in rats and hamsters.

  1995cites this paper
• TMP-153, a novel ACAT inhibitor, lowers plasma cholesterol through its hepatic action in golden hamsters.

  1995cites this paper
• Vascular derived growth factors: cell biology, pathophysiology, and pharmacology.

  1993cites this paper
• Gemfibrozil modifies acyl composition of liver microsomal phospholipids from guinea-pigs without promoting peroxisomal proliferation.

  1993cites this paper
• Cytosolic lipogenic enzymes: effect of fibric acid derivatives in vitro.

  1993cites this paper
• Fibrates modify rat hepatic fatty acid chain elongation and desaturation in vitro.

  1993cites this paper
• Free radicals, lipoproteins and cardiovascular dysfunction.

  1992cites this paper
• Differential inhibition of long-chain acyl-CoA hydrolases by hypolipidemic drugs in vitro.

  1992cites this paper
• Lovastatin prevents the impairment of endothelium dependent relaxation and inhibits accumulation of cholesterol in the aorta in experimental atherosclerosis in rabbits.

  1991cites this paper
• The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs.

  1991cites this paper
• In vitro effect of clofibric acid derivatives on rat hepatic microsomal electron transport chains.

  1991cites this paper
• Biochemical assessment of cardiac function and damage in animal species A Review of the Current Approach of the Academic, Governmental and Industrial Institutions Represented by the Animal Clinical Chemistry Association

  1991cites this paper
• Key issues in the delivery of pharmacological agents using lipoproteins: design of a synthetic apoprotein-lipid carrier.

  1991cites this paper
• Key issues in the delivery of pharmacological agents using lipoproteins: design of a synthetic apoprotein-lipid carrier.

  1991cites this paper